Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.94 SEK | -3.96% | -6.28% | -37.62% |
25/04 | AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
10/04 | Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR). | CI |
Sales 2024 * | - | Sales 2025 * | 60 5.5 458.81 | Capitalization | 125M 11.5M 959M |
---|---|---|---|---|---|
Net income 2024 * | -46M -4.22M -352M | Net income 2025 * | -7M -642K -53.53M | EV / Sales 2024 * | - |
Net cash position 2024 * | 42.5M 3.9M 325M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 20,90,263 x |
P/E ratio 2024 * |
6.73
x | P/E ratio 2025 * |
-1.84
x | Employees | 11 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 36.1% |
1 day | -3.96% | ||
1 week | -6.28% | ||
Current month | +6.59% | ||
1 month | +13.78% | ||
3 months | -40.67% | ||
6 months | -51.13% | ||
Current year | -37.62% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Jönsson
CEO | Chief Executive Officer | 56 | 08/20/08 |
Johan Sandin
FOU | Founder | 54 | 22/16/22 |
Birgitta Lundvik
DFI | Director of Finance/CFO | 57 | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 01/17/01 | |
Ragnar Linder
BRD | Director/Board Member | 71 | 01/17/01 |
Ellen Donnelly
BRD | Director/Board Member | 50 | 01/18/01 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 1.94 | -3.96% | 69 811 |
26/24/26 | 2.02 | -1.46% | 191,004 |
25/24/25 | 2.05 | -2.38% | 186,896 |
24/24/24 | 2.1 | +5.79% | 117,624 |
23/24/23 | 1.985 | -4.11% | 55,256 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 05:48 pm IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-37.62% | 11.44M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.55% | 22.15B | |
-17.37% | 21.02B | |
-8.96% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ALZCUR Stock